Lemaitre Vascular (LMAT) AI Stock Analysis

• Market Cap: $2.17B
• Dividend Yield: 0.75%
• Average Volume (3M): 142.04K
• Price to Earnings (P/E): 46.5
• Beta (1Y): 0.80
• Revenue Growth: 14.11%
• EPS Growth: 23.98%
• Country: US
• Employees: 651
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.60
• Shares Outstanding: 22,637,522
• 10 Day Avg. Volume: 223,841
• 30 Day Avg. Volume: 142,036
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 7.53
• Enterprise Value/Gross Profit: 10.90
• Enterprise Value/Ebitda: 24.44
• 1Y Price Target: $103.00
• Price Target Upside: 7.50% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8

• Rating: 76 Outperform
• Price Target: $105.00 ▲(9.59% Upside)

Lemaitre Vascular's strong financial performance and positive earnings call are the most significant factors driving the stock's score. The company's robust growth and profitability metrics, along with a positive outlook, are key strengths. However, the high valuation and overbought technical indicators present potential risks.

Positive Factors

Financial Performance

LeMaitre Vascular reported strong Q2 results with a 15% organic revenue growth and a 25% operating margin.

Global Demand

LeMaitre's international revenue exceeded expectations, showcasing robust global demand.

Negative Factors

Earnings

EPS of $0.48 fell short relative to the $0.52 estimate as well as the consensus expectation of $0.50.

Operating Margin

The company’s guidance suggests that 2025 is likely to represent a bit of a pause in terms of operating margin expansion.

Lemaitre Vascular Business Overview & Revenue Model

Company Description

Lemaitre Vascular (LMAT) is a medical device company that specializes in the development, manufacturing, and marketing of products for the treatment of vascular diseases. The company primarily focuses on peripheral vascular surgery and offers a range of products including vascular grafts, stent grafts, and other related surgical devices. With a commitment to innovation, Lemaitre Vascular aims to improve patient outcomes through its advanced technologies and products designed for the treatment of various vascular conditions.

How the Company Makes Money

Lemaitre Vascular generates revenue primarily through the sale of its medical devices and products used in vascular surgery. Key revenue streams include direct sales of vascular grafts and stent grafts to hospitals and surgical centers, as well as recurring revenues from the sale of consumables associated with these procedures. The company also benefits from strategic partnerships with healthcare providers and distributors, which expand its market reach and enhance its sales capabilities. Additionally, Lemaitre Vascular invests in research and development to introduce new products, driving future growth and revenue potential.

Lemaitre Vascular Financial Statement Overview

Summary

Lemaitre Vascular demonstrates strong financial health with consistent revenue growth, robust profitability margins, and a stable balance sheet. The company maintains healthy margins, with a gross profit margin of 68.8% and a net profit margin of 19.96%. Cash flow generation is strong, supporting ongoing operations and potential growth initiatives.

Income Statement

Lemaitre Vascular shows strong financial performance with a consistent revenue growth rate, reaching 3.7% in TTM. The company maintains healthy margins, with a gross profit margin of 68.8% and a net profit margin of 19.96% in TTM. EBIT and EBITDA margins are also robust at 25.32% and 27.23%, respectively, indicating efficient operations and profitability.

Balance Sheet

The balance sheet reflects a stable financial position with a manageable debt-to-equity ratio of 0.53 in TTM, suggesting moderate leverage. Return on equity is solid at 13.53%, indicating effective use of equity capital. The equity ratio stands at 62.8%, highlighting a strong equity base relative to total assets.

Cash Flow

Cash flow analysis reveals positive trends, with a significant free cash flow growth rate of 27.24% in TTM. The operating cash flow to net income ratio is 1.94, demonstrating strong cash generation relative to net income. The free cash flow to net income ratio of 0.85 indicates efficient conversion of earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	234.64M	219.86M	193.48M	161.65M	154.42M	129.37M
Gross Profit	162.16M	150.90M	127.05M	104.90M	101.38M	84.62M
EBITDA	72.32M	66.75M	48.99M	36.92M	45.98M	36.89M
Net Income	47.12M	44.04M	30.11M	20.64M	26.91M	21.22M
Balance Sheet
Total Assets	577.59M	551.82M	346.78M	310.48M	292.80M	252.81M
Cash, Cash Equivalents and Short-Term Investments	319.49M	299.72M	105.07M	82.69M	69.96M	26.98M
Total Debt	185.89M	185.69M	19.09M	16.60M	15.94M	54.78M
Total Liabilities	214.91M	214.53M	48.88M	42.27M	38.65M	80.24M
Stockholders Equity	362.69M	337.29M	297.90M	268.20M	254.15M	172.57M
Cash Flow
Free Cash Flow	52.32M	37.16M	29.49M	22.15M	30.22M	31.82M
Operating Cash Flow	58.76M	44.12M	36.75M	25.38M	35.10M	34.80M
Investing Cash Flow	-207.43M	-200.12M	-24.71M	-10.37M	-61.08M	-52.89M
Financing Cash Flow	152.93M	158.10M	-7.13M	-9.23M	13.70M	32.16M

Lemaitre Vascular Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 95.81
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LMAT, the sentiment is Positive. The current price of 95.81 is above the 20-day moving average (MA) of 86.92, above the 50-day MA of 84.59, and above the 200-day MA of 89.89, indicating a bullish trend. The MACD of 3.46 indicates Negative momentum. The RSI at 74.50 is Negative, neither overbought nor oversold. The STOCH value of 90.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LMAT.

Lemaitre Vascular Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LMAT	76 Outperform	$2.17B	46.53	13.81%	0.75%	14.11%	23.98%
ATRC	68 Neutral	$1.76B	―	-7.85%	―	16.28%	10.63%
BLFS	60 Neutral	$1.21B	―	-5.98%	―	-18.61%	92.36%
STAA	56 Neutral	$1.42B	55.81	-25.55%	―	-32.59%	-667.81%
ANGO	55 Neutral	$354.73M	―	-17.50%	―	-3.76%	81.78%
OSUR	54 Neutral	$202.59M	25.27	-12.65%	―	-49.35%	-285.61%
Sector *	47 Neutral	C$213.29M	-1.44	-30.58%	3.10%	19.48%	-0.04%

Lemaitre Vascular Corporate Events

LeMaitre Vascular Appoints Dorian LeBlanc as CFO

On February 7, 2025, LeMaitre Vascular, Inc. announced the appointment of Dorian LeBlanc as Chief Financial Officer, effective March 10, 2025. Mr. LeBlanc brings extensive experience from his previous roles at LumiraDx Limited and Alere Inc., enhancing LeMaitre’s financial leadership. His compensation package includes a base salary, performance bonus, and equity awards, with severance terms outlined in case of termination without cause, signaling a strategic reinforcement of the company’s financial management team.